Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial

Abstract Objectives Innovative post‐remission therapies are needed to eliminate residual AML cells. DC vaccination is a promising strategy to induce anti‐leukaemic immune responses. Methods We conducted a first‐in‐human phase I study using TLR7/8‐matured DCs transfected with RNA encoding the two AML...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Felix S Lichtenegger, Frauke M Schnorfeil, Maurine Rothe, Katrin Deiser, Torben Altmann, Veit L Bücklein, Thomas Köhnke, Christian Augsberger, Nikola P Konstandin, Karsten Spiekermann, Andreas Moosmann, Stephan Boehm, Melanie Boxberg, Mirjam HM Heemskerk, Dennis Goerlich, Georg Wittmann, Beate Wagner, Wolfgang Hiddemann, Dolores J Schendel, Gunnar Kvalheim, Iris Bigalke, Marion Subklewe
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Wiley 2020-01-01
Serie:	Clinical & Translational Immunology
Ämnen:	acute myeloid leukaemia cancer vaccines clinical trials dendritic cell vaccination immunotherapy
Länkar:	https://doi.org/10.1002/cti2.1117
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!